{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:49:15Z","timestamp":1787636955413,"version":"build-2736575974"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00417-025-06816-7","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T23:06:20Z","timestamp":1743894380000},"page":"1755-1763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neuroprotection beyond intraocular pressure: game changer or quiet addiction"],"prefix":"10.1007","volume":"263","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-9382","authenticated-orcid":false,"given":"A.","family":"Grosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Calzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ceruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kostin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Borsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vizzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"6816_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/112067210301303S05","volume":"13","author":"M Schwartz","year":"2003","unstructured":"Schwartz M (2003) Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches. Eur J Ophthalmol 13:27\u201331. https:\/\/doi.org\/10.1177\/112067210301303S05","journal-title":"Eur J Ophthalmol"},{"key":"6816_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S1357-4310(99)01592-0","volume":"5","author":"M Schwartz","year":"1999","unstructured":"Schwartz M, Yoles E, Levin LA (1999) \u2018Axogenic\u2019 and \u2018somagenic\u2019 neurodegenerative diseases: definitions and therapeutic implications. Mol Med Today 5:470\u2013473. https:\/\/doi.org\/10.1016\/S1357-4310(99)01592-0","journal-title":"Mol Med Today"},{"key":"6816_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/01.ijg.0000169412.86387.ad","volume":"14","author":"M Schwartz","year":"2005","unstructured":"Schwartz M (2005) Lessons for glaucoma from other neurodegenerative diseases: can one treatment suit them all? J Glaucoma 14:321\u2013323. https:\/\/doi.org\/10.1097\/01.ijg.0000169412.86387.ad","journal-title":"J Glaucoma"},{"key":"6816_CR4","unstructured":"Lewis RA (2008) Memantine: the day the music died? glaucoma today. https:\/\/glaucomatoday.com\/articles\/2008-mar-apr\/GT0308_medEd-php"},{"key":"6816_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ophtha.2004.10.034","volume":"112","author":"T Krupin","year":"2005","unstructured":"Krupin T, Liebmann JM, Greenfield DS et al (2005) The low-pressure glaucoma treatment study (LoGTS). Ophthalmology 112:376\u2013385. https:\/\/doi.org\/10.1016\/j.ophtha.2004.10.034","journal-title":"Ophthalmology"},{"key":"6816_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/02713683.2019.1663385","volume":"45","author":"TZ Khatib","year":"2020","unstructured":"Khatib TZ, Martin KR (2020) Neuroprotection in glaucoma: towards clinical trials and precision medicine. Curr Eye Res 45:327\u2013338. https:\/\/doi.org\/10.1080\/02713683.2019.1663385","journal-title":"Curr Eye Res"},{"key":"6816_CR7","doi-asserted-by":"publisher","unstructured":"Sena DF, Lindsley K (2017) Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2017. https:\/\/doi.org\/10.1002\/14651858.CD006539.pub4","DOI":"10.1002\/14651858.CD006539.pub4"},{"key":"6816_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinreb","year":"2004","unstructured":"Weinreb RN, Khaw PT (2004) Primary open-angle glaucoma. The Lancet 363:1711\u20131720. https:\/\/doi.org\/10.1016\/S0140-6736(04)16257-0","journal-title":"The Lancet"},{"key":"6816_CR9","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/00061198-200110001-00011","volume":"10","author":"N Gupta","year":"2001","unstructured":"Gupta N, Y\u00fccel YH (2001) Glaucoma and the Brain. J Glaucoma 10:S28\u2013S29. https:\/\/doi.org\/10.1097\/00061198-200110001-00011","journal-title":"J Glaucoma"},{"key":"6816_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.exer.2015.07.004","volume":"141","author":"YH Y\u00fccel","year":"2015","unstructured":"Y\u00fccel YH, Gupta N (2015) A framework to explore the visual brain in glaucoma with lessons from models and man. Exp Eye Res 141:171\u2013178. https:\/\/doi.org\/10.1016\/j.exer.2015.07.004","journal-title":"Exp Eye Res"},{"key":"6816_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","volume":"127","author":"M Saylor","year":"2009","unstructured":"Saylor M (2009) Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent. Arch Ophthalmol 127:402. https:\/\/doi.org\/10.1001\/archophthalmol.2009.9","journal-title":"Arch Ophthalmol"},{"key":"6816_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/IJG.0000000000001565","volume":"29","author":"L Rossetti","year":"2020","unstructured":"Rossetti L, Iester M, Tranchina L et al (2020) Can treatment with citicoline eyedrops reduce progression in Glaucoma? the results of a randomized placebo-controlled clinical trial. J Glaucoma 29:513\u2013520. https:\/\/doi.org\/10.1097\/IJG.0000000000001565","journal-title":"J Glaucoma"},{"key":"6816_CR13","doi-asserted-by":"publisher","unstructured":"Lanza M, Gironi Carnevale UA, Mele L et al (2019) Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: a pilot study with a 2-year follow-up. Front Pharmacol 10. https:\/\/doi.org\/10.3389\/fphar.2019.01117","DOI":"10.3389\/fphar.2019.01117"},{"key":"6816_CR14","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00417-022-05947-5","volume":"261","author":"L Rossetti","year":"2023","unstructured":"Rossetti L, Goni F, Montesano G et al (2023) The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial. Graefe\u2019s Arch Clin Exp Ophthalmol 261:1659\u20131668. https:\/\/doi.org\/10.1007\/s00417-022-05947-5","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"6816_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/ceo.13818","volume":"48","author":"F Hui","year":"2020","unstructured":"Hui F, Tang J, Williams PA et al (2020) Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol 48:903\u2013914. https:\/\/doi.org\/10.1111\/ceo.13818","journal-title":"Clin Exp Ophthalmol"},{"key":"6816_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamaophthalmol.2021.4576","volume":"140","author":"CG De Moraes","year":"2022","unstructured":"De Moraes CG, John SWM, Williams PA et al (2022) Nicotinamide and pyruvate for neuroenhancement in open-angle Glaucoma. JAMA Ophthalmol 140:11. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.4576","journal-title":"JAMA Ophthalmol"},{"key":"6816_CR17","doi-asserted-by":"publisher","first-page":"e0291836","DOI":"10.1371\/journal.pone.0291836","volume":"18","author":"J Prinz","year":"2023","unstructured":"Prinz J, Prokosch V, Liu H et al (2023) Efficacy of citicoline as a supplement in glaucoma patients: a systematic review. PLoS ONE 18:e0291836. https:\/\/doi.org\/10.1371\/journal.pone.0291836","journal-title":"PLoS ONE"},{"key":"6816_CR18","doi-asserted-by":"publisher","unstructured":"Chitu I, Tudosescu R, Leasu-Branet C, Voinea L-M (2017) Citicoline \u2013 a neuroprotector with proven effects on glaucomatous disease. Rom J Ophthalmol 61:152\u2013158. https:\/\/doi.org\/10.22336\/rjo.2017.29","DOI":"10.22336\/rjo.2017.29"},{"key":"6816_CR19","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.3390\/nu12103113","volume":"12","author":"P Jasielski","year":"2020","unstructured":"Jasielski P, Pi\u0119del F, Piwek M et al (2020) Application of citicoline in neurological disorders: a systematic review. Nutrients 12:3113. https:\/\/doi.org\/10.3390\/nu12103113","journal-title":"Nutrients"},{"key":"6816_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF01927720","volume":"30","author":"S Manaka","year":"1974","unstructured":"Manaka S, Sano K, Fuchinoue T, Sekino H (1974) Mechanism of action of CDP-choline in parkinsonism. Experientia 30:179\u2013180. https:\/\/doi.org\/10.1007\/BF01927720","journal-title":"Experientia"},{"key":"6816_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0166-2236(92)90351-8","volume":"15","author":"RJ Wurtman","year":"1992","unstructured":"Wurtman RJ (1992) Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci 15:117\u2013122. https:\/\/doi.org\/10.1016\/0166-2236(92)90351-8","journal-title":"Trends Neurosci"},{"key":"6816_CR22","doi-asserted-by":"publisher","unstructured":"Shanks HRC, Onuska KM, Barupal DK, Schmitz TW (2022) Serum unsaturated phosphatidylcholines predict longitudinal basal forebrain degeneration in Alzheimer\u2019s disease. Brain Commun 4. https:\/\/doi.org\/10.1093\/braincomms\/fcac318","DOI":"10.1093\/braincomms\/fcac318"},{"key":"6816_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1046\/j.0022-3042.2001.00697.x","volume":"80","author":"RM Adibhatla","year":"2002","unstructured":"Adibhatla RM, Hatcher JF, Dempsey RJ (2002) Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 80:12\u201323. https:\/\/doi.org\/10.1046\/j.0022-3042.2001.00697.x","journal-title":"J Neurochem"},{"key":"6816_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.physbeh.2018.08.002","volume":"195","author":"M Roohi-Azizi","year":"2018","unstructured":"Roohi-Azizi M, Torkaman-Boutorabi A, Akhondzadeh S et al (2018) Influence of citicoline on citalopram-induced antidepressant activity in depressive-like symptoms in male mice. Physiol Behav 195:151\u2013157. https:\/\/doi.org\/10.1016\/j.physbeh.2018.08.002","journal-title":"Physiol Behav"},{"key":"6816_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.nbd.2004.10.006","volume":"18","author":"O Hurtado","year":"2005","unstructured":"Hurtado O, Moro MA, C\u00e1rdenas A et al (2005) Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis 18:336\u2013345. https:\/\/doi.org\/10.1016\/j.nbd.2004.10.006","journal-title":"Neurobiol Dis"},{"key":"6816_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.neuint.2011.12.015","volume":"60","author":"M Guti\u00e9rrez-Fern\u00e1ndez","year":"2012","unstructured":"Guti\u00e9rrez-Fern\u00e1ndez M, Rodr\u00edguez-Frutos B, Fuentes B et al (2012) CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int 60:310\u2013317. https:\/\/doi.org\/10.1016\/j.neuint.2011.12.015","journal-title":"Neurochem Int"},{"key":"6816_CR27","doi-asserted-by":"publisher","first-page":"e0269224","DOI":"10.1371\/journal.pone.0269224","volume":"17","author":"A Agarwal","year":"2022","unstructured":"Agarwal A, Vishnu VY, Sharma J et al (2022) Citicoline in acute ischemic stroke: a randomized controlled trial. PLoS ONE 17:e0269224. https:\/\/doi.org\/10.1371\/journal.pone.0269224","journal-title":"PLoS ONE"},{"key":"6816_CR28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1749-6632.1996.tb34452.x","volume":"777","author":"R Cacabelos","year":"1996","unstructured":"Cacabelos R, Caama\u00f1o J, G\u00f3mez MJ et al (1996) Therapeutic effects of CDP-choline in Alzheimer\u2019s disease-cognition, brain mapping, cerebrovascular hemodynamics, and immune factorsa. Ann N Y Acad Sci 777:399\u2013403. https:\/\/doi.org\/10.1111\/j.1749-6632.1996.tb34452.x","journal-title":"Ann N Y Acad Sci"},{"key":"6816_CR29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1358\/mf.1999.21.9.795632","volume":"21","author":"XA Alvarez","year":"1999","unstructured":"Alvarez XA, Mouzo R, Pichel V et al (1999) Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer\u2019s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol 21:633\u2013644","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"6816_CR30","first-page":"597","volume":"16","author":"A Franco-Maside","year":"1994","unstructured":"Franco-Maside A, Caama\u00f1o J, G\u00f3mez MJ, Cacabelos R (1994) Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer\u2019s disease. Methods Find Exp Clin Pharmacol 16:597\u2013607","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"6816_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000117914","volume":"8","author":"A Agnoli","year":"1982","unstructured":"Agnoli A, Ruggieri S, Denaro A, Bruno G (1982) New strategies in the management of Parkinson\u2019s disease: a biological approach using a phospholipid precursor (CDP-Choline). Neuropsychobiology 8:289\u2013296. https:\/\/doi.org\/10.1159\/000117914","journal-title":"Neuropsychobiology"},{"key":"6816_CR32","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/0028-3908(87)90093-1","volume":"26","author":"TC Saligau","year":"1987","unstructured":"Saligau TC, Daoust M, Moore N, Boismare F (1987) Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: Changes induced by oral administration of cytidine-5\u2019-diphosphocholine\u2606. Neuropharmacology 26:1315\u20131319. https:\/\/doi.org\/10.1016\/0028-3908(87)90093-1","journal-title":"Neuropharmacology"},{"key":"6816_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF02569065","volume":"93","author":"EC Campos","year":"1997","unstructured":"Campos EC, Bolzani R, Schiavi C et al (1997) Cytidin-5\u2032-diphosphocholine enhances the effect of part-time occlusion in amblyopia. Doc Ophthalmol 93:247\u2013263. https:\/\/doi.org\/10.1007\/BF02569065","journal-title":"Doc Ophthalmol"},{"key":"6816_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00417-007-0621-6","volume":"246","author":"M Fresina","year":"2008","unstructured":"Fresina M, Dickmann A, Salerni A et al (2008) Effect of oral CDP-choline on visual function in young amblyopic patients. Graefe\u2019s Arch Clin Exp Ophthalmol 246:143\u2013150. https:\/\/doi.org\/10.1007\/s00417-007-0621-6","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"6816_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/0301-4738.128586","volume":"62","author":"P Pawar","year":"2014","unstructured":"Pawar P, Mumbare S, Patil M, Ramakrishnan S (2014) Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. Indian J Ophthalmol 62:124. https:\/\/doi.org\/10.4103\/0301-4738.128586","journal-title":"Indian J Ophthalmol"},{"key":"6816_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1076\/ceyr.17.2.141.5606","volume":"17","author":"V Porciatti","year":"1998","unstructured":"Porciatti V, Schiavi C, Benedetti P et al (1998) Cytidine-5\u2019-diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Curr Eye Res 17:141\u2013148. https:\/\/doi.org\/10.1076\/ceyr.17.2.141.5606","journal-title":"Curr Eye Res"},{"key":"6816_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1468-1331.2008.02099.x","volume":"15","author":"V Parisi","year":"2008","unstructured":"Parisi V, Coppola G, Ziccardi L et al (2008) Cytidine-5\u2032-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol 15:465\u2013474. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02099.x","journal-title":"Eur J Neurol"},{"key":"6816_CR38","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0161-6420(99)90269-5","volume":"106","author":"V Parisi","year":"1999","unstructured":"Parisi V, Manni G, Colacino G, Bucci MG (1999) Cytidine-5\u2032-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma11The authors have no proprietary interest in the development or marketing of this or a competing drug. Ophthalmology 106:1126\u20131134. https:\/\/doi.org\/10.1016\/S0161-6420(99)90269-5","journal-title":"Ophthalmology"},{"key":"6816_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/0301-4738.133484","volume":"62","author":"G Roberti","year":"2014","unstructured":"Roberti G, Tanga L, Parisi V et al (2014) A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol 62:549. https:\/\/doi.org\/10.4103\/0301-4738.133484","journal-title":"Indian J Ophthalmol"},{"key":"6816_CR40","doi-asserted-by":"publisher","first-page":"e0224982","DOI":"10.1371\/journal.pone.0224982","volume":"14","author":"C Carnevale","year":"2019","unstructured":"Carnevale C, Manni G, Roberti G et al (2019) Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution. PLoS ONE 14:e0224982. https:\/\/doi.org\/10.1371\/journal.pone.0224982","journal-title":"PLoS ONE"},{"key":"6816_CR41","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00417-015-3044-9","volume":"253","author":"V Parisi","year":"2015","unstructured":"Parisi V, Centofanti M, Ziccardi L et al (2015) Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefe\u2019s Arch Clin Exp Ophthalmol 253:1327\u20131340. https:\/\/doi.org\/10.1007\/s00417-015-3044-9","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"6816_CR42","unstructured":"Rejdak R, Toczo\u0142owski J, Kurkowski J, et al (2003) Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 9:PI24\u20138"},{"key":"6816_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000350496","volume":"229","author":"L Ottobelli","year":"2013","unstructured":"Ottobelli L, Manni GL, Centofanti M et al (2013) Citicoline oral solution in Glaucoma: is there a role in slowing disease progression? Ophthalmologica 229:219\u2013226. https:\/\/doi.org\/10.1159\/000350496","journal-title":"Ophthalmologica"},{"key":"6816_CR44","doi-asserted-by":"publisher","first-page":"483","DOI":"10.18240\/ijo.2022.03.17","volume":"15","author":"AK Sahin","year":"2022","unstructured":"Sahin AK, Uzun A (2022) Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma. Int J Ophthalmol 15:483\u2013488. https:\/\/doi.org\/10.18240\/ijo.2022.03.17","journal-title":"Int J Ophthalmol"},{"key":"6816_CR45","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.3390\/molecules25235614","volume":"25","author":"P Marino","year":"2020","unstructured":"Marino P, Rossi G, Campagna G et al (2020) Effects of citicoline, homotaurine, and Vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: a preliminary study. Molecules 25:5614. https:\/\/doi.org\/10.3390\/molecules25235614","journal-title":"Molecules"},{"key":"6816_CR46","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.3390\/life12101481","volume":"12","author":"A Anton","year":"2022","unstructured":"Anton A, Garcia V, Mu\u00f1oz M et al (2022) The effect of oral citicoline and docosahexaenoic acid on the visual field of patients with Glaucoma: a randomized trial. Life 12:1481. https:\/\/doi.org\/10.3390\/life12101481","journal-title":"Life"},{"key":"6816_CR47","unstructured":"Kolomeyer Natasha Nayak (2022) Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin. Clinical Trial NCT04784234 Wills Eye Hospital, Glaucoma Research Center, Philadelphia"},{"key":"6816_CR48","unstructured":"Parisi Vincenzo (2023) Multimodal morpho-functional study in glaucoma patients-citicoline oral solution. Clinical Trial NCT05315206\u00a0128\/21\/FB Fondazione Bietti, Rome, Italy"},{"key":"6816_CR49","unstructured":"(2023) Effect of MEMOPTIC on Visual Field of Patients Followed for a Chronic Open-angle Glaucoma (MEMO-GCAO).\u00a0Clinical Trial NCT04499157 Centre Hospitalier Universitaire, Amiens"},{"key":"6816_CR50","unstructured":"(2023) Efficacy of Citicoline Eye Drops 2% on visual field preservation in patients with open angle glaucoma.\u00a0Clinical trial NCT05710198 Omikron Italia S.r.l"},{"key":"6816_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02028649","volume":"13","author":"JP Giraldi","year":"1989","unstructured":"Giraldi JP, Virno M, Covelli G et al (1989) Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol 13:109\u2013112. https:\/\/doi.org\/10.1007\/BF02028649","journal-title":"Int Ophthalmol"},{"key":"6816_CR52","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/IJG.0b013e318279b836","volume":"23","author":"V Parisi","year":"2014","unstructured":"Parisi V, Centofanti M, Gandolfi S et al (2014) Effects of Coenzyme Q10 in Conjunction With Vitamin E on Retinal-evoked and Cortical-evoked Responses in Patients With Open-angle Glaucoma. J Glaucoma 23:391\u2013404. https:\/\/doi.org\/10.1097\/IJG.0b013e318279b836","journal-title":"J Glaucoma"},{"key":"6816_CR53","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","volume":"119","author":"EE Chang","year":"2012","unstructured":"Chang EE, Goldberg JL (2012) Glaucoma 2.0: Neuroprotection, Neuroregeneration. Neuroenhancement Ophthalmology 119:979\u2013986. https:\/\/doi.org\/10.1016\/j.ophtha.2011.11.003","journal-title":"Neuroenhancement Ophthalmology"},{"key":"6816_CR54","doi-asserted-by":"publisher","first-page":"e105931","DOI":"10.1371\/journal.pone.0105931","volume":"9","author":"P Frezzotti","year":"2014","unstructured":"Frezzotti P, Giorgio A, Motolese I et al (2014) Structural and functional brain changes beyond visual system in patients with advanced Glaucoma. PLoS ONE 9:e105931. https:\/\/doi.org\/10.1371\/journal.pone.0105931","journal-title":"PLoS ONE"},{"key":"6816_CR55","first-page":"838","volume":"17","author":"D Gaasterland","year":"1978","unstructured":"Gaasterland D, Tanishima T, Kuwabara T (1978) Axoplasmic flow during chronic experimental glaucoma. 1. Light and electron microscopic studies of the monkey optic nervehead during development of glaucomatous cupping. Invest Ophthalmol Vis Sci 17:838\u2013846","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6816_CR56","first-page":"3451","volume":"41","author":"TW Mittag","year":"2000","unstructured":"Mittag TW, Danias J, Pohorenec G et al (2000) Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 41:3451\u20133459","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6816_CR57","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1167\/iovs.05-1639","volume":"47","author":"KK Abu-Amero","year":"2006","unstructured":"Abu-Amero KK, Morales J, Bosley TM (2006) Mitochondrial abnormalities in patients with primary open-angle Glaucoma. Investig Opthalmol Vis Sci 47:2533. https:\/\/doi.org\/10.1167\/iovs.05-1639","journal-title":"Investig Opthalmol Vis Sci"},{"key":"6816_CR58","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.exer.2010.03.008","volume":"90","author":"NN Osborne","year":"2010","unstructured":"Osborne NN (2010) Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp Eye Res 90:750\u2013757. https:\/\/doi.org\/10.1016\/j.exer.2010.03.008","journal-title":"Exp Eye Res"},{"key":"6816_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.exer.2010.07.015","volume":"93","author":"S Lee","year":"2011","unstructured":"Lee S, Van Bergen NJ, Kong GY et al (2011) Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp Eye Res 93:204\u2013212. https:\/\/doi.org\/10.1016\/j.exer.2010.07.015","journal-title":"Exp Eye Res"},{"key":"6816_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.coph.2012.09.008","volume":"13","author":"V Chrysostomou","year":"2013","unstructured":"Chrysostomou V, Rezania F, Trounce IA, Crowston JG (2013) Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 13:12\u201315. https:\/\/doi.org\/10.1016\/j.coph.2012.09.008","journal-title":"Curr Opin Pharmacol"},{"key":"6816_CR61","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1167\/iovs.13-12564","volume":"55","author":"D Lee","year":"2014","unstructured":"Lee D, Shim MS, Kim K-Y et al (2014) Coenzyme Q10 inhibits glutamate excitotoxicity and oxidative stress-mediated mitochondrial alteration in a mouse model of Glaucoma. Investig Opthalmol Vis Sci 55:993. https:\/\/doi.org\/10.1167\/iovs.13-12564","journal-title":"Investig Opthalmol Vis Sci"},{"key":"6816_CR62","doi-asserted-by":"publisher","first-page":"e1105","DOI":"10.1038\/cddis.2014.80","volume":"5","author":"SY Kim","year":"2014","unstructured":"Kim SY, Shim MS, Kim K-Y et al (2014) Inhibition of cyclophilin D by cyclosporin A promotes retinal ganglion cell survival by preventing mitochondrial alteration in ischemic injury. Cell Death Dis 5:e1105\u2013e1105. https:\/\/doi.org\/10.1038\/cddis.2014.80","journal-title":"Cell Death Dis"},{"key":"6816_CR63","doi-asserted-by":"publisher","first-page":"e108090","DOI":"10.1371\/journal.pone.0108090","volume":"9","author":"H Cheng","year":"2014","unstructured":"Cheng H, Ding Y, Yu R et al (2014) Neuroprotection of a Novel Cyclopeptide C*HSDGIC* from the Cyclization of PACAP (1\u20135) in Cellular and Rodent Models of Retinal Ganglion Cell Apoptosis. PLoS ONE 9:e108090. https:\/\/doi.org\/10.1371\/journal.pone.0108090","journal-title":"PLoS ONE"},{"key":"6816_CR64","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.2741\/4343","volume":"20","author":"VP Skulachev","year":"2015","unstructured":"Skulachev VP (2015) Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits. Front Biosci 20:4343. https:\/\/doi.org\/10.2741\/4343","journal-title":"Front Biosci"},{"key":"6816_CR65","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1126\/science.aal0092","volume":"355","author":"PA Williams","year":"1979","unstructured":"Williams PA, Harder JM, Foxworth NE et al (1979) (2017) Vitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science 355:756\u2013760. https:\/\/doi.org\/10.1126\/science.aal0092","journal-title":"Science"},{"key":"6816_CR66","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/IJG.0000000000000767","volume":"26","author":"PA Williams","year":"2017","unstructured":"Williams PA, Harder JM, John SWM (2017) Glaucoma as a metabolic optic neuropathy: making the case for nicotinamide treatment in Glaucoma. J Glaucoma 26:1161\u20131168. https:\/\/doi.org\/10.1097\/IJG.0000000000000767","journal-title":"J Glaucoma"},{"key":"6816_CR67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/ICU.0000000000000558","volume":"30","author":"TJ Wubben","year":"2019","unstructured":"Wubben TJ, Zacks DN, Besirli CG (2019) Retinal neuroprotection. Curr Opin Ophthalmol 30:199\u2013205. https:\/\/doi.org\/10.1097\/ICU.0000000000000558","journal-title":"Curr Opin Ophthalmol"},{"key":"6816_CR68","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ajo.2015.05.030","volume":"160","author":"I Zucchiatti","year":"2015","unstructured":"Zucchiatti I, Parodi MB, Pierro L et al (2015) Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration. Am J Ophthalmol 160:602-607.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.05.030","journal-title":"Am J Ophthalmol"},{"key":"6816_CR69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.61.3.2","volume":"61","author":"M Trinh","year":"2020","unstructured":"Trinh M, Tong J, Yoshioka N et al (2020) Macula ganglion cell thickness changes display location-specific variation patterns in intermediate age-related macular degeneration. Investig Opthalmol Vis Sci 61:2. https:\/\/doi.org\/10.1167\/iovs.61.3.2","journal-title":"Investig Opthalmol Vis Sci"},{"key":"6816_CR70","doi-asserted-by":"publisher","first-page":"102030","DOI":"10.1016\/j.pdpdt.2020.102030","volume":"32","author":"S Ozcaliskan","year":"2020","unstructured":"Ozcaliskan S, Artunay O, Balci S et al (2020) Quantitative analysis of inner retinal structural and microvascular alterations in intermediate age-related macular degeneration: a swept-source OCT angiography study. Photodiagnosis Photodyn Ther 32:102030. https:\/\/doi.org\/10.1016\/j.pdpdt.2020.102030","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"6816_CR71","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s00417-021-05140-0","volume":"259","author":"C Farinha","year":"2021","unstructured":"Farinha C, Silva AL, Coimbra R et al (2021) Retinal layer thicknesses and neurodegeneration in early age-related macular degeneration: insights from the Coimbra Eye Study. Graefe\u2019s Arch Clin Exp Ophthalmol 259:2545\u20132557. https:\/\/doi.org\/10.1007\/s00417-021-05140-0","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"6816_CR72","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/IAE.0000000000001759","volume":"38","author":"IK Muftuoglu","year":"2018","unstructured":"Muftuoglu IK, Ramkumar HL, Bartsch D-U et al (2018) Quantitative analysis of the inner retinal layer thicknesses in age-related macular degeneration using corrected optical coherence tomography segmentation. Retina 38:1478\u20131484. https:\/\/doi.org\/10.1097\/IAE.0000000000001759","journal-title":"Retina"},{"key":"6816_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000468965","volume":"238","author":"P Camacho","year":"2017","unstructured":"Camacho P, Dutra-Medeiros M, P\u00e1ris L (2017) Ganglion cell complex in early and intermediate age-related macular degeneration: evidence by SD-OCT manual segmentation. Ophthalmologica 238:31\u201343. https:\/\/doi.org\/10.1159\/000468965","journal-title":"Ophthalmologica"},{"key":"6816_CR74","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1007\/s10792-023-02758-3","volume":"43","author":"SH Narnaware","year":"2023","unstructured":"Narnaware SH, Bansal A, Bawankule PK et al (2023) Vessel density changes in choroid, chorio-capillaries, deep and superficial retinal plexues on OCTA in normal ageing and various stages of age-related macular degeneration. Int Ophthalmol 43:3523\u20133532. https:\/\/doi.org\/10.1007\/s10792-023-02758-3","journal-title":"Int Ophthalmol"},{"key":"6816_CR75","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1167\/iovs.64.4.21","volume":"64","author":"E Borrelli","year":"2023","unstructured":"Borrelli E, Barresi C, Lari G et al (2023) Capturing the transition from intermediate to neovascular AMD: longitudinal inner retinal thinning and factors associated with neuronal loss. Investigative Opthalmology & Visual Science 64:21. https:\/\/doi.org\/10.1167\/iovs.64.4.21","journal-title":"Investigative Opthalmology & Visual Science"},{"key":"6816_CR76","doi-asserted-by":"publisher","unstructured":"(2001) A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss. Archives of Ophthalmology 119:1417. https:\/\/doi.org\/10.1001\/archopht.119.10.1417","DOI":"10.1001\/archopht.119.10.1417"},{"key":"6816_CR77","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.ophtha.2013.01.021","volume":"120","author":"EY Chew","year":"2013","unstructured":"Chew EY, Clemons TE, Agr\u00f3n E et al (2013) Long-term effects of vitamins C and E, \u03b2-carotene, and Zinc on age-related macular degeneration. Ophthalmology 120:1604-1611.e4. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.021","journal-title":"Ophthalmology"},{"key":"6816_CR78","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1167\/iovs.10-5637","volume":"51","author":"WT Wong","year":"2010","unstructured":"Wong WT, Kam W, Cunningham D et al (2010) Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Investig Opthalmol Vis Sci 51:6131. https:\/\/doi.org\/10.1167\/iovs.10-5637","journal-title":"Investig Opthalmol Vis Sci"},{"key":"6816_CR79","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.xops.2021.100095","volume":"2","author":"MJ Allingham","year":"2022","unstructured":"Allingham MJ, Mettu PS, Cousins SW (2022) Phase 1 clinical trial of elamipretide in intermediate age-related macular degeneration and high-risk drusen. Ophthalmol Sci 2:100095. https:\/\/doi.org\/10.1016\/j.xops.2021.100095","journal-title":"Ophthalmol Sci"},{"key":"6816_CR80","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1073\/pnas.1018987108","volume":"108","author":"K Zhang","year":"2011","unstructured":"Zhang K, Hopkins JJ, Heier JS et al (2011) Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci 108:6241\u20136245. https:\/\/doi.org\/10.1073\/pnas.1018987108","journal-title":"Proc Natl Acad Sci"},{"key":"6816_CR81","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1167\/iovs.04-0598","volume":"45","author":"DN Zacks","year":"2004","unstructured":"Zacks DN, Zheng Q-D, Han Y et al (2004) FAS-mediated apoptosis and its relation to intrinsic pathway activation in an experimental model of retinal detachment. Investig Opthalmol Vis Sci 45:4563. https:\/\/doi.org\/10.1167\/iovs.04-0598","journal-title":"Investig Opthalmol Vis Sci"},{"key":"6816_CR82","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajo.2010.09.026","volume":"151","author":"T Krupin","year":"2011","unstructured":"Krupin T, Liebmann JM, Greenfield DS et al (2011) A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol 151:671\u2013681. https:\/\/doi.org\/10.1016\/j.ajo.2010.09.026","journal-title":"Am J Ophthalmol"},{"key":"6816_CR83","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(14)62111-5","volume":"385","author":"DF Garway-Heath","year":"2015","unstructured":"Garway-Heath DF, Crabb DP, Bunce C et al (2015) Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. The Lancet 385:1295\u20131304. https:\/\/doi.org\/10.1016\/S0140-6736(14)62111-5","journal-title":"The Lancet"},{"key":"6816_CR84","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.exer.2015.05.008","volume":"141","author":"V Porciatti","year":"2015","unstructured":"Porciatti V (2015) Electrophysiological assessment of retinal ganglion cell function. Exp Eye Res 141:164\u2013170. https:\/\/doi.org\/10.1016\/j.exer.2015.05.008","journal-title":"Exp Eye Res"},{"key":"6816_CR85","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.3390\/ijms23105751","volume":"23","author":"V Porciatti","year":"2022","unstructured":"Porciatti V, Chou T-H (2022) Using noninvasive electrophysiology to determine time windows of neuroprotection in optic neuropathies. Int J Mol Sci 23:5751. https:\/\/doi.org\/10.3390\/ijms23105751","journal-title":"Int J Mol Sci"},{"key":"6816_CR86","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1167\/iovs.12-11026","volume":"54","author":"MR Banitt","year":"2013","unstructured":"Banitt MR, Ventura LM, Feuer WJ et al (2013) Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci 54:2346. https:\/\/doi.org\/10.1167\/iovs.12-11026","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6816_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ophtha.2004.09.002","volume":"112","author":"L Ventura","year":"2005","unstructured":"Ventura L, Porciatti V (2005) Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study. Ophthalmology 112:20\u201327. https:\/\/doi.org\/10.1016\/j.ophtha.2004.09.002","journal-title":"Ophthalmology"},{"key":"6816_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ophtha.2004.07.018","volume":"112","author":"L Ventura","year":"2005","unstructured":"Ventura L, Porciatti V, Ishida K et al (2005) Pattern electroretinogram abnormality and glaucoma. Ophthalmology 112:10\u201319. https:\/\/doi.org\/10.1016\/j.ophtha.2004.07.018","journal-title":"Ophthalmology"},{"key":"6816_CR89","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1167\/iovs.11-8525","volume":"53","author":"LM Ventura","year":"2012","unstructured":"Ventura LM, Feuer WJ, Porciatti V (2012) Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma. Invest Ophthalmol Vis Sci 53:659. https:\/\/doi.org\/10.1167\/iovs.11-8525","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6816_CR90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IJG.0b013e31819f934e","volume":"19","author":"G Vizzeri","year":"2010","unstructured":"Vizzeri G, Tafreshi A, Weinreb RN, Bowd C (2010) Effect of operator and optical defocus on the variability of pattern electroretinogram optimized for glaucoma detection (PERGLA). J Glaucoma 19:77\u201382. https:\/\/doi.org\/10.1097\/IJG.0b013e31819f934e","journal-title":"J Glaucoma"},{"key":"6816_CR91","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ophtha.2008.10.026","volume":"116","author":"C Bowd","year":"2009","unstructured":"Bowd C, Vizzeri G, Tafreshi A et al (2009) Diagnostic accuracy of pattern electroretinogram optimized for glaucoma detection. Ophthalmology 116:437\u2013443. https:\/\/doi.org\/10.1016\/j.ophtha.2008.10.026","journal-title":"Ophthalmology"},{"key":"6816_CR92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/IJG.0b013e31818c6f44","volume":"18","author":"C Bowd","year":"2009","unstructured":"Bowd C, Tafreshi A, Vizzeri G et al (2009) Repeatability of pattern electroretinogram measurements using a new paradigm optimized for glaucoma detection. J Glaucoma 18:437\u2013442. https:\/\/doi.org\/10.1097\/IJG.0b013e31818c6f44","journal-title":"J Glaucoma"},{"key":"6816_CR93","doi-asserted-by":"publisher","first-page":"100976","DOI":"10.1016\/j.preteyeres.2021.100976","volume":"86","author":"MF Cordeiro","year":"2022","unstructured":"Cordeiro MF, Hill D, Patel R et al (2022) Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic. Prog Retin Eye Res 86:100976. https:\/\/doi.org\/10.1016\/j.preteyeres.2021.100976","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"6816_CR94","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.coph.2012.09.003.96","volume":"13","author":"AP Cherecheanu","year":"2013","unstructured":"Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L (2013) Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol 13(1):36\u201342. https:\/\/doi.org\/10.1016\/j.coph.2012.09.003.96","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"6816_CR95","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1080\/02713683.2020.1752390","volume":"45","author":"AS Mursch-Edlmayr","year":"2020","unstructured":"Mursch-Edlmayr AS, Pickl L, Calzetti G et al (2020) Comparison of neurovascular coupling between normal tension glaucoma patients and healthy individuals with laser speckle flowgraphy. Curr Eye Res 45(11):1438\u20131442. https:\/\/doi.org\/10.1080\/02713683.2020.1752390","journal-title":"Curr Eye Res"},{"key":"6816_CR96","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.ymthe.2024.04.030","volume":"32","author":"F Xia","year":"2024","unstructured":"Xia F, Shi S, Palacios E et al (2024) Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma. Mol Ther 32:1760\u20131778. https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.030","journal-title":"Mol Ther"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06816-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T10:22:10Z","timestamp":1757154130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06816-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":96,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6816"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06816-7","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}